Topical Application of Tranexamic Acid Reduces Postoperative Blood Loss in Total Hip Arthroplasty

Inclusion Criteria: * Patient who are to undergo elective total hip arthroplasty. * Must be primary arthroplasty. * Must be single-side arthroplasty. * Must be older than 18 years. Exclusion Criteria: * Cemented arthroplasty. * Patients with a platelet count less than 100, 000/mm3 or history of thrombocytopenia . * Patients with known coagulopathy (APTT or PT outside normal range pre-operatively). * Patients who have a past medical history of thrombi-embolism at any time. * Patients with anemia (hemoglobin levels less than 8 mg/dl or hematocrit \<24%). * Patients with documented DVT or PE at screening or in past three months. * Patients having known hypersensitivity to tranexamic acid or any other. constituent of the product. * Patients with any associated major illness (e.g., severe cardiac \[New York Heart Association Class III or IV\] or respiratory disease). * Anticoagulants (other than LMWH or heparin in prophylactic doses to prevent deep vein thrombosis), direct thrombin inhibitors or thrombolytic therapy administered or completed within last week. * Jehovah's Witnesses, or any other group of patients with ethical objections to receiving blood products.